Targets › SLC31A2
1 program from 1 company in 3 trials: 3 Phase 2; Oncology; next expected readout May 2027.
Does not function as a copper(1+) importer in vivo (By similarity). However, in vitro functions as a low-affinity copper(1+) importer. (UniProt, O15432)
Open in Phaseline: the race on SLC31A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Privo Technologies | PRV111 (Cisplatin Transmucosal System) Transmucosal cisplatin patch delivery system | SLC31A2 | Phase 2 | Oral Squamous Cell Carcinoma | May 2027 |
Oral Squamous Cell Carcinoma (3)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.